Skye Bioscience, Inc.
OTC:SKYE
Overview | Financials
| Company Name | Skye Bioscience, Inc. |
| Symbol | SKYE |
| Currency | USD |
| Price | 4.12 |
| Market Cap | 127,672,208 |
| Dividend Yield | 0% |
| 52-week-range | 1.14 - 7.11 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Mr. Punit S. Dhillon B.A., BA |
| Website | https://skyebioscience.com |
An error occurred while fetching data.
About Skye Bioscience, Inc.
Skye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100, which is in Phase I trials for the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 that is in preclinical trials to
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD



